Christopher A. Callahan
Salk Institute for Biological Studies
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christopher A. Callahan.
Nature | 2006
John Ridgway; Gu Zhang; Yan Wu; Scott Stawicki; Wei Ching Liang; Yvan Chanthery; Joe Kowalski; Ryan J. Watts; Christopher A. Callahan; Ian Kasman; Mallika Singh; May Chien; Christine Tan; Jo Anne Hongo; Fred de Sauvage; Greg Plowman; Minhong Yan
Haploinsufficiency of Dll4, a vascular-specific Notch ligand, has shown that it is essential for embryonic vascular development and arteriogenesis. Mechanistically, it is unclear how the Dll4-mediated Notch pathway contributes to complex vascular processes that demand meticulous coordination of multiple signalling pathways. Here we show that Dll4-mediated Notch signalling has a unique role in regulating endothelial cell proliferation and differentiation. Neutralizing Dll4 with a Dll4-selective antibody rendered endothelial cells hyperproliferative, and caused defective cell fate specification or differentiation both in vitro and in vivo. In addition, blocking Dll4 inhibited tumour growth in several tumour models. Remarkably, antibodies against Dll4 and antibodies against vascular endothelial growth factor (VEGF) had paradoxically distinct effects on tumour vasculature. Our data also indicate that Dll4-mediated Notch signalling is crucial during active vascularization, but less important for normal vessel maintenance. Furthermore, unlike blocking Notch signalling globally, neutralizing Dll4 had no discernable impact on intestinal goblet cell differentiation, supporting the idea that Dll4-mediated Notch signalling is largely restricted to the vascular compartment. Therefore, targeting Dll4 might represent a broadly efficacious and well-tolerated approach for the treatment of solid tumours.
Nature | 2010
Yan Wu; Carol Cain-Hom; Lisa Choy; Thijs J. Hagenbeek; Gladys P. de Leon; Yongmei Chen; David Finkle; Rayna Venook; Xiumin Wu; John Ridgway; Dorreyah Schahin-Reed; Graham J. Dow; Amy Shelton; Scott Stawicki; Ryan J. Watts; Jeff Zhang; Robert Choy; Peter Howard; Lisa C. Kadyk; Minhong Yan; Jiping Zha; Christopher A. Callahan; Sarah G. Hymowitz; Christian W. Siebel
The four receptors of the Notch family are widely expressed transmembrane proteins that function as key conduits through which mammalian cells communicate to regulate cell fate and growth. Ligand binding triggers a conformational change in the receptor negative regulatory region (NRR) that enables ADAM protease cleavage at a juxtamembrane site that otherwise lies buried within the quiescent NRR. Subsequent intramembrane proteolysis catalysed by the γ-secretase complex liberates the intracellular domain (ICD) to initiate the downstream Notch transcriptional program. Aberrant signalling through each receptor has been linked to numerous diseases, particularly cancer, making the Notch pathway a compelling target for new drugs. Although γ-secretase inhibitors (GSIs) have progressed into the clinic, GSIs fail to distinguish individual Notch receptors, inhibit other signalling pathways and cause intestinal toxicity, attributed to dual inhibition of Notch1 and 2 (ref. 11). To elucidate the discrete functions of Notch1 and Notch2 and develop clinically relevant inhibitors that reduce intestinal toxicity, we used phage display technology to generate highly specialized antibodies that specifically antagonize each receptor paralogue and yet cross-react with the human and mouse sequences, enabling the discrimination of Notch1 versus Notch2 function in human patients and rodent models. Our co-crystal structure shows that the inhibitory mechanism relies on stabilizing NRR quiescence. Selective blocking of Notch1 inhibits tumour growth in pre-clinical models through two mechanisms: inhibition of cancer cell growth and deregulation of angiogenesis. Whereas inhibition of Notch1 plus Notch2 causes severe intestinal toxicity, inhibition of either receptor alone reduces or avoids this effect, demonstrating a clear advantage over pan-Notch inhibitors. Our studies emphasize the value of paralogue-specific antagonists in dissecting the contributions of distinct Notch receptors to differentiation and disease and reveal the therapeutic promise in targeting Notch1 and Notch2 independently.
Proceedings of the National Academy of Sciences of the United States of America | 2011
Weiwei Chen; Tracy Tang; Jeff Eastham-Anderson; Debra Dunlap; Bruno Alicke; Michelle Nannini; Stephen Jay Gould; Robert L. Yauch; Zora Modrusan; Kelly J. DuPree; Walter C. Darbonne; Greg Plowman; Frederic J. de Sauvage; Christopher A. Callahan
Hedgehog (Hh) signaling is critical to the patterning and development of a variety of organ systems, and both ligand-dependent and ligand-independent Hh pathway activation are known to promote tumorigenesis. Recent studies have shown that in tumors promoted by Hh ligands, activation occurs within the stromal microenvironment. Testing whether ligand-driven Hh signaling promotes tumor angiogenesis, we found that Hh antagonism reduced the vascular density of Hh-producing LS180 and SW480 xenografts. In addition, ectopic expression of sonic hedgehog in low-Hh–expressing DLD-1 xenografts increased tumor vascular density, augmented angiogenesis, and was associated with canonical Hh signaling within perivascular tumor stromal cells. To better understand the molecular mechanisms underlying Hh-mediated tumor angiogenesis, we established an Hh-sensitive angiogenesis coculture assay and found that fibroblast cell lines derived from a variety of human tissues were Hh responsive and promoted angiogenesis in vitro through a secreted paracrine signal(s). Affymetrix array analyses of cultured fibroblasts identified VEGF-A, hepatocyte growth factor, and PDGF-C as candidate secreted proangiogenic factors induced by Hh stimulation. Expression studies of xenografts and angiogenesis assays using combinations of Hh and VEGF-A inhibitors showed that it is primarily Hh-induced VEGF-A that promotes angiogenesis in vitro and augments tumor-derived VEGF to promote angiogenesis in vivo.
Mechanisms of Development | 1993
M.G. Muralidhar; Christopher A. Callahan; John B. Thomas
Proper development of the midline cells within the Drosophila central nervous system is controlled by the single-minded (sim) gene. The sim protein defines a new subclass of bHLH transcription factors and as such, is predicted to function as a transcriptional regulator of other genes important for midline development. Here we identify two potential targets of sim regulation: the sim gene itself, and the 47F gene, which is expressed specifically in the sim-expressing midline cells. Using a transgene containing sim regulatory sequences fused to beta-galactosidase, we show that the sim gene uses two distinct promoters with overlapping temporal specificities, and that expression from the late promoter is autoregulated by sim itself. By expressing sim protein in salivary gland nuclei using the heat-shock inducible Hsp70 gene promoter, we show that sim protein associates with the sim late promoter on polytene chromosomes. In addition, sim protein binds to a small number of additional chromosomal sites, among which are the sites of the 47F gene, and two other genes, Tl and cdi, whose expression also depend on sim function.
Development | 1995
Scott E. Lundgren; Christopher A. Callahan; Stefan Thor; John B. Thomas
Nature | 1995
Christopher A. Callahan; M.G. Muralidhar; Scott E. Lundgren; Audra L. Scully; John B. Thomas
Proceedings of the National Academy of Sciences of the United States of America | 1994
Christopher A. Callahan; John B. Thomas
Development | 1996
Christopher A. Callahan; Joshua L. Bonkovsky; Audra L. Scully; John B. Thomas
Archive | 2011
Maike Schmidt; Christopher A. Callahan; Jo-Anne Hongo; Hartmut Koeppen; Ryan J. Watts
Archive | 2011
Maike Schmidt; Christopher A. Callahan; Jo-Anne Hongo; Hartmut Koeppen; Ryan J. Watts